NOTICE OF PENDENCY OF CLASS ACTION: Please be advised that your rights may be affected by the above-captioned securities class action (the “Action”) pending in the United States District Court for the District of New Jersey (the “Court”), if you purchased the publicly traded common stock of Eagle Pharmaceuticals, Inc. between August 9, 2022 and October 1, 2024, both dates inclusive (the “Settlement Class Period”).¹

NOTICE OF SETTLEMENT: Please also be advised that the Court-appointed lead plaintiff Evans Associates I, LLC (“Lead Plaintiff”) and named plaintiffs Nicholas Miller, Liyu Wang, and Joanna Pluta (together with Lead Plaintiff, “Plaintiffs”), on behalf of themselves and the Settlement Class (as defined in ¶ 29 below), have reached a proposed settlement of the Action for $9,500,000 in cash that, if approved, will resolve all claims in the Action (the “Settlement”).

This Notice relates to a proposed Settlement of claims in a pending securities class action brought by investors alleging, among other things, that defendants Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”), and defendants Scott Tarriff and Brian Cahill (collectively, “Individual Defendants”; and together with Eagle, “Defendants”) violated the federal securities laws by making false and misleading statements regarding sales of Eagle’s drug Pemfexy.

Court-appointed Lead Counsel, Glancy Prongay Wolke & Rotter LLP (“Lead Counsel”) and liaison counsel Carella, Byrne, Cecchi, Brody & Agnello, P.C (“Liaison Counsel”), which have been prosecuting the Action on a wholly contingent basis since their appointment by the Court in 2024, and additional counsel for Plaintiffs, Jack I. Zwick, Esq., and the Law Offices of Frank R. Cruz, have not received any payment of attorneys’ fees for their representation of the Settlement Class and have advanced the funds to pay expenses necessarily incurred to prosecute this Action.